What does this research mean for the field?

SGLT2 inhibitors significantly reduce the risk of heart failure hospitalizations and improve overall survival in heart failure patients, regardless of their diabetes status. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

March 3, 2026Experimental and Therapeutic MedicineOpen Access

SGLT2i significantly reduced the risk of first hospitalization for HF (OR=0.76; 95% CI: 0.64-0.91; P=0.002; I²=0%) and total hospitalization for HF (OR=0.67; 95% CI: 0.63-0.72; P<0.00001; I²=33%).

View Full Paper

Ask AI

Bookmark

Why the study?

SGLT2 inhibitors have cardiovascular and renal protective effects beyond glucose lowering, warranting an evaluation of their efficacy in reducing HF hospitalizations, CV mortality, and adverse events in patients with and without type 2 diabetes mellitus.

Do SGLT2 inhibitors reduce heart failure hospitalizations and mortality in adults with heart failure regardless of diabetes status?

Population

Adults with HF irrespective of ejection fraction or diabetes status across 28 RCTs

Comparison

SGLT2i vs placebo or standard-of-care

Design

Systematic review and meta-analysis of randomized controlled trials

Authors

DBDuaa Bafail NANoura Hamdi Yousef Alhalees

Discussion

Member takes

Overview

Supports SGLT2i use in HF independent of diabetes; reinforces consistent benefit across 28 RCTs.

Key Points

SGLT2 inhibitors significantly reduced heart failure hospitalizations by 24% and total hospitalizations by 33%.
All-cause and cardiovascular mortality were decreased by 28% and 24%, respectively, due to SGLT2 inhibitors.
Data were analyzed from 28 randomized controlled trials, highlighting the treatment's benefits across diabetic and non-diabetic populations.
The findings suggest SGLT2 inhibitors support heart failure management, with a low risk of bias in most studies.

Structured PICO

Do SGLT2 inhibitors reduce heart failure hospitalizations and mortality in adults with heart failure regardless of diabetes status?

Population

Adults with heart failure, irrespective of ejection fraction or diabetes status (28 RCTs)

Intervention

SGLT2 inhibitors

Comparator

Placebo or standard-of-care

Outcome

Heart failure hospitalizations (first and total), cardiovascular mortality, all-cause mortality, adverse events, and patient-reported quality of life measureshard clinical

SGLT2 inhibitors effectively reduce heart failure hospitalizations and improve survival in a broad spectrum of heart failure patients, including those without diabetes.

Limitations

Significant publication bias in studies addressing total hospitalization

Cite This Study

Bafail et al. (2026) studied this question.

synapsesocial.com/papers/69a75bbdc6e9836116a239f1 https://doi.org/10.3892/etm.2026.13079

View Full Paper

Ask AI

Bookmark

March 3, 2026Experimental and Therapeutic MedicineOpen Access

SGLT2i significantly reduced the risk of first hospitalization for HF (OR=0.76; 95% CI: 0.64-0.91; P=0.002; I²=0%) and total hospitalization for HF (OR=0.67; 95% CI: 0.63-0.72; P<0.00001; I²=33%).

View Full Paper

Ask AI

Bookmark

Why the study?

Do SGLT2 inhibitors reduce heart failure hospitalizations and mortality in adults with heart failure regardless of diabetes status?

Population

Adults with HF irrespective of ejection fraction or diabetes status across 28 RCTs

Comparison

SGLT2i vs placebo or standard-of-care

Design

Systematic review and meta-analysis of randomized controlled trials

Authors

DBDuaa Bafail NANoura Hamdi Yousef Alhalees

Discussion

Member takes

Overview

Supports SGLT2i use in HF independent of diabetes; reinforces consistent benefit across 28 RCTs.

Key Points

SGLT2 inhibitors significantly reduced heart failure hospitalizations by 24% and total hospitalizations by 33%.
All-cause and cardiovascular mortality were decreased by 28% and 24%, respectively, due to SGLT2 inhibitors.
Data were analyzed from 28 randomized controlled trials, highlighting the treatment's benefits across diabetic and non-diabetic populations.
The findings suggest SGLT2 inhibitors support heart failure management, with a low risk of bias in most studies.

Structured PICO

Do SGLT2 inhibitors reduce heart failure hospitalizations and mortality in adults with heart failure regardless of diabetes status?

Population

Adults with heart failure, irrespective of ejection fraction or diabetes status (28 RCTs)

Intervention

SGLT2 inhibitors

Comparator

Placebo or standard-of-care

Outcome

Heart failure hospitalizations (first and total), cardiovascular mortality, all-cause mortality, adverse events, and patient-reported quality of life measureshard clinical

SGLT2 inhibitors effectively reduce heart failure hospitalizations and improve survival in a broad spectrum of heart failure patients, including those without diabetes.

Limitations

Significant publication bias in studies addressing total hospitalization

Cite This Study

Bafail et al. (2026) studied this question.

synapsesocial.com/papers/69a75bbdc6e9836116a239f1 https://doi.org/10.3892/etm.2026.13079

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark